XL184 20mg Pill - gray capsule/oblong
Generic Name: cabozantinib
Pill with imprint XL184 20mg is Gray, Capsule/Oblong and has been identified as Cometriq 20 mg. It is supplied by Exelixis, Inc.
Cometriq is used in the treatment of Thyroid Cancer and belongs to the drug classes multikinase inhibitors, VEGF/VEGFR inhibitors. There is positive evidence of human fetal risk during pregnancy. Cometriq 20 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for XL184 20mg
Cometriq
- Generic Name
- cabozantinib
- Imprint
- XL184 20mg
- Strength
- 20 mg
- Color
- Gray
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Multikinase inhibitors, VEGF/VEGFR inhibitors
- Pregnancy Category
- D - Positive evidence of risk
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Exelixis, Inc.
- National Drug Code (NDC)
- 42388-0014
- Inactive Ingredients
-
microcrystalline cellulose,
croscarmellose sodium,
sodium starch glycolate type A potato,
silicon dioxide,
stearic acid,
gelatin,
ferrosoferric oxide,
titanium dioxide,
shellac,
butyl alcohol,
isopropyl alcohol,
propylene glycol,
ammonia
Note: Inactive ingredients may vary.
More about Cometriq (cabozantinib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
